Alterity Therapeutics soared over 36% in premarket trading.Alterity Therapeutics (ASX:ATH) secured a US patent for compounds to treat neurodegenerative diseases, including Parkinson's and Alzheimer's diseases.
The patent covers more than 80 compounds and secures exclusivity for a new class of iron chaperones, which would redistribute excess iron implicated in many neurodegenerative diseases, according to a Thursday news release.